Dana Farber Cancer Institute, U.S.
New research from the United States and South Korea in the area of cancer treatment detailed
Published in Food and Drug Law Weekly, August 25th, 2006
Study 1: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
According to a study from the United States, "Perifosine is a synthetic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibits Akt activation. Here we show that baseline phosphorylation of Akt in multiple myeloma (MM) cells is completely inhibited by perifosine [octadecyl-(1,1-d imethyl-piperidinio-4-yl)-phosphate] in a time- and dose-dependent fashion, without...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
More Articles from Food and Drug Law Weekly
- Abbott
Abbott gets U.S. FDA clearance for test to diagnose congestive heart failure - Aida Pharmaceuticals
Aida Pharmaceuticals completes phase I trials for gene-therapy drug - Bovie Medical
Bovie Medical reports U.S. FDA clears suture removal device for marketing - Chembio Diagnostics
Chembio applies for CLIA Waiver for SURE CHECK HIV 1/2, go-ahead would expand domestic marketing - EMD Chemicals
EMD Chemicals gets U.S. FDA approval for Candurin for use in drugs - Elan
Biogen Idec, Elan announce availability of Tysabri to treat relapsing forms of multiple sclerosis - More from this issue of Food and Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
